Exparel indications expanded to include adductor canal and sacral nerve blocks

The FDA has approved bupivacaine liposome injectable suspension (Exparel) for postsurgical regional anesthesia in adults as 1) an adductor canal block and 2) a sciatic nerve block in the popliteal fossa. Previously Exparel had been approved in adults for postsurgical regional anesthesia as an interscalene brachial plexus nerve block, and for local analgesia via infiltration in patients ages 6 years and older.